Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Metabolic Dysfunction-Associated Steatohepatitis – Access & Reimbursement – Access & Reimbursement – Nonalcoholic Steatohepatitis in the Top 5 European Markets
MARKET OUTLOOKNon-alcoholic steatohepatitis (NASH) is rapidly becoming an important public health issue in the top five European markets (France, Germany, Italy, Spain, UK). High prevalence of this…
Immune Checkpoint Inhibitors – Access & Reimbursement – Access and Reimbursement – Immune Checkpoint Inhibitors: Top Five European Markets (EU)
Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, and Roche’s Tecentriq, are revolutionizing the therapeutic strategies for several cancers. This…
Psoriasis – Access & Reimbursement – Access and Reimbursement – Psoriasis: Top 5 European Markets (EU)
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and…
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access and Reimbursement – Atopic Dermatitis/Atopic Eczema: Top 5 European Markets (EU)
MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…
Non-Small-Cell Lung Cancer (The Dynamic NSCLC Market: How Will European Payer and Physician Attitudes Shape This Highly Lucrative Market?) | Physician & Payer Forum | EU5 | 2015
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…
Systemic Lupus Eryhtematosus (What Market Access Levers and Barriers Will Emerging Biologics for SLE Face in Europe?) | Physician & Payer Forum | EU5 | 2014
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
